Multiple Sclerosis, Relapsing-Remitting

"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Descriptor ID	D020529
MeSH Number(s)	C10.114.375.500.600 C10.314.350.500.600 C20.111.258.250.500.600
Concept/Terms	Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Relapsing Remitting Remitting-Relapsing Multiple Sclerosis Multiple Sclerosis, Remitting-Relapsing Remitting Relapsing Multiple Sclerosis Relapsing-Remitting Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Multiple Sclerosis, Acute Relapsing Multiple Sclerosis, Acute Relapsing Acute Relapsing Multiple Sclerosis

Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".

Diseases [C]
Nervous System Diseases [C10]
Autoimmune Diseases of the Nervous System [C10.114]
Demyelinating Autoimmune Diseases, CNS [C10.114.375]
Multiple Sclerosis [C10.114.375.500]
Multiple Sclerosis, Relapsing-Remitting [C10.114.375.500.600]
Demyelinating Diseases [C10.314]
Demyelinating Autoimmune Diseases, CNS [C10.314.350]
Multiple Sclerosis [C10.314.350.500]
Multiple Sclerosis, Relapsing-Remitting [C10.314.350.500.600]
Immune System Diseases [C20]
Autoimmune Diseases [C20.111]
Autoimmune Diseases of the Nervous System [C20.111.258]
Demyelinating Autoimmune Diseases, CNS [C20.111.258.250]
Multiple Sclerosis [C20.111.258.250.500]
Multiple Sclerosis, Relapsing-Remitting [C20.111.258.250.500.600]

Below are MeSH descriptors whose meaning is related to "Multiple Sclerosis, Relapsing-Remitting".

Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in this website by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publications.

Bar chart showing 20 publications over 13 distinct years, with a maximum of 3 publications in 2011 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2000	1	1
2001	1	1
2003	1	1
2007	1	1
2011	3	3
2015	2	2
2016	1	1
2018	1	1
2019	1	1
2020	2	2
2021	2	2
2022	1	1
2023	3	3

Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 10; 13(5):261-268.

View in: PubMed
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 05 18; 13(1):8067.

View in: PubMed
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.

View in: PubMed
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.

View in: PubMed
Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.

View in: PubMed
De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Mult Scler. 2022 01; 28(1):111-120.

View in: PubMed
Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs. 2020 Dec; 80(18):1901-1928.

View in: PubMed
Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102572.

View in: PubMed
Hudgens S, Sch?ler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis. Value Health. 2019 04; 22(4):453-466.

View in: PubMed
Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord. 2019 Apr; 29:157-167.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement